Early Diagnosis of Therapy-associated Cardiotoxicity Basing on Multi-tracer Multimodality PET/MRI

Peking University Cancer Hospital & Institute

Status: Unknown

Conditions: Magnetic Resonance Imaging; Positron-Emission Tomography

Study type: Observational

Funder types: Other

Identifiers

NCT04555642

XW-Heart-001

Details and patient eligibility

About

Using Multi-tracer to early diagnosis of therapy-associated cardiotoxicity using multimodality PET/MRI.

Full description

In this study investigators evaluated cardiac uptake by different molecular probe such as FDG, FAPI-04 using multimodality PET/MRI. Previous studies have shown that increased cardiac uptake of FDG on PET may be an indicator of myocardial injury after chemotherapy. Cardiac magnetic resonance (CMR) allows for multiparametric evaluation of cardiac morphology, ventricular function, myocardial perfusion, and viability. The combination of PET with MR (PET/MR) is therefore an alternative attractive pairing for diagnostic imaging. The aim of this study is to find noninvasive and effective method for early diagnosis of cardiotoxicity after chemotherapy or immunotherapy

Enrollment: 120 estimated patients

Sex: All

Ages: 18 to 75 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• availability of a clinical pre- and post-therapy clinical evaluation encompassing electrocardiogram (ECG) ;
• normal findings at pre-therapy clinical evaluation;
• cancer planned chemotherapy or immunotherapy scheme ;
• available staging FDG-PET/CT scan (PET0);

Exclusion criteria

• cannot lie supine for half an hour;
• refuse to join the clinical researcher;
• without metal implants.

Trial design

120 participants in 2 patient groups

therapy group

Description:

lymphoma patients planned chemotherapy or immunotherapy scheme

healthy control group

Description:

Inclusion criteria for the controls were no known diseases or syndromes, within the age range from 18 to 35 years.